These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7414647)

  • 1. [Reliability of the diagnostic results obtained with confined quantities of the contrast medium in endolymphatic radionuclide therapy (ELRT) of the inferior limbs (author's transl)].
    Müller RP; Schnepper E; Peters PE; Fladerer W
    Strahlentherapie; 1980 Aug; 156(8):538-41. PubMed ID: 7414647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lymphographically detectable long-term changes caused by endolymphatic radionuclide therapy (ELRT) in the infradiaphragmatic lymph system].
    Müller RP; Peters PE
    Strahlentherapie; 1985 Apr; 161(4):239-43. PubMed ID: 2986321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Endolymphatic radionuclide therapy of the malignant melanoma (author's transl)].
    Makoski HB; Scherer E; Magnus L; Verbeek W
    Strahlentherapie; 1978 Mar; 154(3):169-73. PubMed ID: 635942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical results of endolymphatic radionuclide therapy in the treatment of malignant melanoma].
    Makoski HB; Magnus L; Heissen E; Kolpatzik H; Drepper H
    Strahlentherapie; 1974 Jul; 148(1):1-15. PubMed ID: 4612879
    [No Abstract]   [Full Text] [Related]  

  • 5. [Radiation dose to the lung following endolymphatic radionuclide therapy of melanoma of the lower limbs].
    Müller RP; Peters PE
    Strahlentherapie; 1985 Jan; 161(1):23-9. PubMed ID: 2982221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vitality evaluation of malignant melanoma metastases following endolymphatic radionuclide therapy using the Falck-Hillarp method].
    Paul E; Illig L; Möller W
    Hautarzt; 1975 Jun; 26(6):317-20. PubMed ID: 1165195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Scintigraphic examinations of the lymph before endolymphatic radionuclide therapy of the malignant melanoma of the inferior extremity (author's transl)].
    Müller RP; Vosberg H; Peters PE; Hemmelskamp S
    Strahlentherapie; 1979 Apr; 155(4):243-7. PubMed ID: 452049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution pattern of radioactive labelled lipiodol-UF following intralymphatic application for therapy.
    Weissleder H; Pfannenstiel P; Peters PE
    Lymphology; 1976 Sep; 9(3):122-6. PubMed ID: 187879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of a digital whole body scanner to the dosimetry of intralymphatic 32P/131I Lipiodol.
    O'Connell EA; Steere HA; Trott NG
    Br J Radiol; 1976 Sep; 49(585):779-87. PubMed ID: 183852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of endolymphatic therapy with radionuclides.
    Peters PE; Weissleder H
    Lymphology; 1974 Mar; 7(1):49-52. PubMed ID: 4851228
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of melanoma by endolymphatic therapy.
    Edwards JM; Kinmonth JB
    Panminerva Med; 1976; 18(5-6):183-6. PubMed ID: 1264472
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of melanoma by endolymphatic therapy.
    Edwards JM
    Proc R Soc Med; 1974 Feb; 67(2):97-9. PubMed ID: 4821237
    [No Abstract]   [Full Text] [Related]  

  • 13. [Dose distribution in healthy and metastatic lymph nodes after endolymphatic radionuclide therapy. II. Rabbit experiments using 32phosphorus-tri-n-octyl-phosphate and 125 iodine-trioleate in lipidol UF].
    Magnus L
    Strahlentherapie; 1973 Jun; 145(6):631-43. PubMed ID: 4375316
    [No Abstract]   [Full Text] [Related]  

  • 14. [Radiation therapy of malignant melanoma (author's transl)].
    Scherer E; Makoski HB
    Langenbecks Arch Chir; 1976 Nov; 342():545-8. PubMed ID: 825693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lymphography for malignant melanoma (author's transl)].
    von Fischer B; Göthlin J; Fuchs WA
    Fortschr Geb Rontgenstr Nuklearmed; 1974 Aug; 121(2):224-30. PubMed ID: 4371467
    [No Abstract]   [Full Text] [Related]  

  • 16. Endolymphatic isotope and BCG in the management of malignant melanoma.
    Edwards JM; Pheils PJ
    Aust N Z J Surg; 1978 Feb; 48(1):40-8. PubMed ID: 276347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The advantages of lymphography in malignant melanoma (author's transl)].
    Trigalo I; Courthalac F; Desprez-Curely JP; Banzet P
    Sem Hop; 1982 Mar; 58(11):687-92. PubMed ID: 6278616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lymphogenous formation of metastases in malignant melanoma].
    Wolf G; Czech W; Pulitzer B
    Radiologe; 1973 Nov; 13(11):485-91. PubMed ID: 4779091
    [No Abstract]   [Full Text] [Related]  

  • 19. [Dose distribution in healthy lymph nodes and in lymph nodes affected by metastases after endolymphatic therapy with radionuclides].
    Magnus L
    Strahlentherapie; 1973 May; 145(5):571-81. PubMed ID: 4761818
    [No Abstract]   [Full Text] [Related]  

  • 20. [Results of lymphographic course controls following endolymphatic radionuclide therapy].
    Wolf G
    Med Welt; 1974 Jun; 25(23):1050-4. PubMed ID: 4410764
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.